Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 19, 2012, Pages 6286-6291

  Banerjee, Abhisek ^a   Patil, Sandip ^a   Pawar, Mahesh Y ^a   Gullapalli, Srinivas ^a   Gupta, Praveen K ^a   Gandhi, Maulik N ^a   Bhateja, Deepak K ^a   Bajpai, Malini ^a   Sangana, Ramachandra Rao ^a   Gudi, Girish S ^a   Khairatkar Joshi, Neelima ^a   Gharat, Laxmikant A ^a  

^a Glenmark Pharmaceuticals Limited   (India)

Author keywords

CNS penetration; Haloperidol; Imidazopyridazinone; MPTP; Parkinson's disease; PDE7

Indexed keywords

BENSERAZIDE; HALOPERIDOL; IMIDAZOLE DERIVATIVE; LEVODOPA; PHOSPHODIESTERASE VII INHIBITOR; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINONE DERIVATIVE; PYRROLIDINE DERIVATIVE; ROLIPRAM; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; HYDROGENATION; HYDROLYSIS; IC 50; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARKINSON DISEASE; PHARMACOKINETICS; PHARMACOLOGY; PLASMA CONCENTRATION-TIME CURVE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PARKINSON DISEASE; PYRIDONES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 84866354283     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.07.077     Document Type: Article

References (25)

1. M.A. Giembycz, and S.J. Smith Drugs Future 31 2006 207
2. M.G. Tansey, M.K. McCoy, and T.C. Frank-Cannon Exp. Neurol. 208 2007 1
3. E.G. McGeer, and P.L. McGeer CNS Drugs 21 2007 789
4. J.A. Morales-Garcia, M. Redondo, S. Alonso-Gil, C. Gil, C. Perez, A. Martinez, A. Santos, and A. Perez-Castillo PLoS ONE 6 2011 e17240
5. The role of PDE7 inhibitors to enhancing neuroprotection in wellcharacterized cellular and animal models of spinal cord injury, stroke and multiple sclerosis is demonstrated in the following references, respectively. (a) Paterniti, I.; Mazzon, E.; Gil, C.; Impllizzari, D.; Palomo, V.; Redondo, M.; Perez, D. I.; Esposito, E.; Martinez, A.; Cuzzocrea, S. PLoS ONE 2011, 6, e15937;
6. (b) Redondo, M.; Zarruk, J. G.; Ceballos, P.; Pérez, D. I.; Pérez, C.; Perez-Castillo, A.; Moro, M. A.; Brea, J.; Val, C.; Cadavid, M. I.; Loza, M. I.; Campillo, N. E.; Martínez, A.; Gil, C. Eur. J. Med. Chem. 2012, 47, 175;
7. (c) Redondo, M.; Brea, J.; Perez, D. I.; Soteras, I.; Val, C.; Perez, C.; Morales-García, J. A.; Alonso-Gil, S.; Paul-Fernandez, N.; Martin-Alvarez, R.; Cadavid, M. I.; Loza, M. I.; Perez-Castillo, A.; Mengod, G.; Campillo, N. E.; Martinez, A.; Gil, C. J. Med. Chem. 2012, 55, 3274.
8. R.L. Albin, A.B. Young, and J.B. Penney Trends Neurosci. 12 1989 366
9. M.R. DeLong Trends Neurosci. 13 1990 281
10. Bergmann, J. E.; Cutshall, N. S.; Demopulos, G. A.; Florio, V. A.; Gaitanaris, G.; Gray, P.; Hohmann, J.; Onrust, R.; Honhkui, Z. U.S. Pat. Appl. 2010, US 0113486.
11. A. Banerjee, P.S. Yadav, M. Bajpai, R.R. Sangana, S. Gullapalli, G.S. Gudi, and L.A. Gharat Bioorg. Med. Chem. Lett. 22 2012 3223
12. F. Vergne, P. Bernardelli, and E. Chevalier Annu. Rep. Med. Chem. 40 2005 227
13. C. Gil, N.E. Campillo, D.I. Perez, and A. Martinez Expert Opin. Ther. Patents 18 2008 1127
14. S.V. Gres'ko, N.N. Smolyar, and Y.M. Yutilov Russian J. Org. Chem. 1026 2001 37
15. C. Sette, S. Iona, and M. Conti J. Biol. Chem. 269 1994 9245
16. J.M. Hetman, S.H. Soderling, N.A. Glavas, and J.A. Beavo Proc. Natl. Acad. Sci. 97 2000 472
17. R. Kurosaki, Y. Muramatsu, H. Kato, and T. Araki Pharmacol. Biochem. Behav. 78 2004 143
18. A. Fredriksson, A. Plaznik, E. Sundstrom, G. Jonsson, and T. Archer Pharmacol. Toxicol. 67 1990 295 MPTP (4 × 20 mg/kg in saline) was injected to 8-10 week old male C57BL/6 mice subcutaneously in a single day at 2 h intervals 7 days prior to behavioral test. On day 5 and 6, the mice were subjected to behavioral locomotor activity (Med Associates Activity Monitor Env-520, software version 4.21) to assess the disease progression and allocation into treatment groups. On day 7, compound 7 and l-dopa/benserazide were administered 15 and 30 min. prior to the test (MPTP study was performed at Numira Biosciences, Bothell, WA, USA). Horizontal activity was registered when mice move in the horizontal plane around the cage by interruption of low grid of infra-red beams. Rearing was registered as the vertical activity when at least one high-level beam was broken, that is the number of counts was proportional to the time spent rearing
19. D. Boulay, O. Bergis, P. Avenet, and G. Griebel Neuropsychopharmacol. 35 2010 416 The effect of compound 7 per se and on haloperidol induced cataleptogenic activity was assessed in catalepsy bar test at 0.5 and 1 h post administration. Compound 7 and haloperidol were administered as intraperitonealy (i.p.) and subcutaneously (s.c.), respectively. Cataleptic-like behavior was addressed by positioning the mouse in an upright position with its forepaws resting on a horizontal bar (0.5 cm diameter) fixed at 4 cm height above the surface of the bench. The time during which each mouse maintained this position (the two front paws resting on the bar) was recorded up to a maximum of 300 sec. The latency for mice to remove the forepaws and climb down to a normal posture was recorded. In the combination study, compound 7 was pretreated 15 min. prior to haloperidol administration
20. P. Onali, M.C. Olianas, and G.L. Gessa Mol. Pharmacol. 28 1985 138
21. M. Kaneko, K. Sato, R. Horikoshi, M. Yaginuma, N. Yaginuma, M. Shiragata, and H. Kumashiro Prostaglandins Leukot. Essent. Fatty Acids 46 1992 53
22. J.A. Siuciak, D.S. Chapin, S.A. McCarthy, and A.N. Martin Psychopharmacol. 192 2007 415
23. O.A. Salam, and S. Nada Turk. J. Med. Sci. 41 2011 693
24. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, M.L. Corman, M. Hajos, J.F. Harms, W.E. Hoffman, L.A. Lebel, S.A. McCarthy, F.R. Nelson, C. Proulx-LaFrance, M.J. Majchrzak, A.D. Ramirez, P.A. Schmidt, P.A. Seymour, J.A. Siuciak, F.D. Tingley III, R.D. Williams, P.R'. Verhoest, and F.S. Menniti J. Pharmacol. Exp. Ther. 325 2008 681
25. S.M. Grauer, V.L. Pulito, R.L. Navarra, M.P. Kelley, C. Kelley, R. Graf, B. Langen, S. Logue, J. Brennan, L. Jiang, E. Charych, U. Egerland, F. Liu, K.L. Marquis, M. Malamas, T. Hage, T.A. Comery, and N.J. Brandon Pharmacol. Exp. Ther. 331 2009 574